BACKGROUND: Cysteinyl leukotriene release in association with airway inflammation is a feature of clinical asthma. The acute effects of montelukast (MK-0476), a potent, orally administered, specific cysteinyl leukotriene receptor antagonist, on airways obstruction was assessed in patients with mild to moderately severe asthma. METHODS:Twenty two asthmatic subjects were randomised to receive montelukast, 100 mg or 250 mg, or placebo in a double blind, three period, crossover trial. Ten of the patients were using concomitant inhaled corticosteroids. RESULTS:Montelukast increased the forced expiratory volume in one second (FEV1) from predose baseline values compared with placebo, the percentage point differences between montelukast and placebo being 8.6% (95% CI 3.6 to 13.6) and 8.5% (95% CI 3.5 to 13.5) for the 100 mg and 250 mg doses, respectively. CONCLUSION: Single oral doses of montelukast 100 mg and 250 mg produced significant increases in FEV1 irrespective of the concurrent use of inhaled corticosteroids in asthmatic subjects with airflow limitation.
RCT Entities:
BACKGROUND:Cysteinyl leukotriene release in association with airway inflammation is a feature of clinical asthma. The acute effects of montelukast (MK-0476), a potent, orally administered, specific cysteinyl leukotriene receptor antagonist, on airways obstruction was assessed in patients with mild to moderately severe asthma. METHODS: Twenty two asthmatic subjects were randomised to receive montelukast, 100 mg or 250 mg, or placebo in a double blind, three period, crossover trial. Ten of the patients were using concomitant inhaled corticosteroids. RESULTS:Montelukast increased the forced expiratory volume in one second (FEV1) from predose baseline values compared with placebo, the percentage point differences between montelukast and placebo being 8.6% (95% CI 3.6 to 13.6) and 8.5% (95% CI 3.5 to 13.5) for the 100 mg and 250 mg doses, respectively. CONCLUSION: Single oral doses of montelukast 100 mg and 250 mg produced significant increases in FEV1 irrespective of the concurrent use of inhaled corticosteroids in asthmatic subjects with airflow limitation.
Authors: N Impens; T F Reiss; J A Teahan; M Desmet; T H Rossing; S Shingo; J Zhang; W Schandevyl; R Verbesselt; A G Dupont Journal: Am Rev Respir Dis Date: 1993-06
Authors: M L Cloud; G C Enas; J Kemp; T Platts-Mills; L C Altman; R Townley; D Tinkelman; T King; E Middleton; A L Sheffer Journal: Am Rev Respir Dis Date: 1989-11
Authors: T R Jones; M Labelle; M Belley; E Champion; L Charette; J Evans; A W Ford-Hutchinson; J Y Gauthier; A Lord; P Masson Journal: Can J Physiol Pharmacol Date: 1995-02 Impact factor: 2.273
Authors: Bing Han; Guoyang Luo; Zheng-Zheng Shi; Roberto Barrios; Donna Atwood; Weili Liu; Geetha M Habib; Richard N Sifers; David B Corry; Michael W Lieberman Journal: Am J Pathol Date: 2002-08 Impact factor: 4.307